From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 261-267

  Angell, Helen ^a,b   Galon, Jérôme ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CANCER VACCINE; CYTOTOXIC AGENT; DENDRITIC CELL VACCINE; FLUOROURACIL; IPILIMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TOLL LIKE RECEPTOR AGONIST; TUMOR MARKER; VASCULOTROPIN ANTIBODY;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE MARKER; DRUG EFFICACY; HUMAN; IMMUNOSCORE; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877076923     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.03.004     Document Type: Review

References (80)

1. Galon J., Fridman W.H., Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007, 67:1883-1886.
2. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
3. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306.
4. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., Camus M., Gillard M., Bruneval P., Fridman W.H., et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-1440.
5. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
6. Tefany F.J., Barnetson R.S., Halliday G.M., McCarthy S.W., McCarthy W.H. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991, 97:197-202.
7. Mackensen A., Ferradini L., Carcelain G., Triebel F., Faure F., Viel S., Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 1993, 53:3569-3573.
8. Clark W.H., Elder D.E., Guerry Dt, Braitman L.E., Trock B.J., Schultz D., Synnestvedt M., Halpern A.C. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893-1904.
9. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
10. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104:3360-3365.
11. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
12. Badoual C., Hans S., Rodriguez J., Peyrard S., Klein C., Agueznay Nel H., Mosseri V., Laccourreye O., Bruneval P., Fridman W.H., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12:465-472.
13. Reichert T.E., Scheuer C., Day R., Wagner W., Whiteside T.L. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001, 91:2136-2147.
14. Shibuya T.Y., Nugyen N., McLaren C.E., Li K.T., Wei W.Z., Kim S., Yoo G.H., Rogowski A., Ensley J., Sakr W. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res 2002, 8:745-751.
15. Nakakubo Y., Miyamoto M., Cho Y., Hida Y., Oshikiri T., Suzuoki M., Hiraoka K., Itoh T., Kondo S., Katoh H. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003, 89:1736-1742.
16. Sharma P., Shen Y., Wen S., Yamada S., Jungbluth A.A., Gnjatic S., Bajorin D.F., Reuter V.E., Herr H., Old L.J., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007, 104:3967-3972.
17. Alexe G., Dalgin G.S., Scanfeld D., Tamayo P., Mesirov J.P., DeLisi C., Harris L., Barnard N., Martel M., Levine A.J., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007, 67:10669-10676.
18. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., Ellis I.O., Green A.R. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955.
19. Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L., Freeman S.M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997, 74:492-501.
20. Menegaz R.A., Michelin M.A., Etchebehere R.M., Fernandes P.C., Murta E.F. Peri- and intratumoral T and B lymphocytic infiltration in breast cancer. Eur J Gynaecol Oncol 2008, 29:321-326.
21. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58:3491-3494.
22. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
23. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., Bruneval P., Trajanoski Z., Fridman W.H., Pages F., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29:610-618.
24. Sinicrope F.A., Rego R.L., Ansell S.M., Knutson K.L., Foster N.R., Sargent D.J. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137:1270-1279.
25. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., Platell C., Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192.
26. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pages F., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271.
27. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Lagorce C., Wind P., Marliot F., Bruneval P., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951.
28. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., Costes A., Bindea G., Charoentong P., Bruneval P., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69:2685-2693.
29. Baker K., Zlobec I., Tornillo L., Terracciano L., Jass J.R., Lugli A. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer 2007, 43:624-631.
30. Dalerba P., Maccalli C., Casati C., Castelli C., Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003, 46:33-57.
31. Diederichsen A.C., Hjelmborg J.B., Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003, 52:423-428.
32. Halama N., Michel S., Kloor M., Zoernig I., Pommerencke T., von Knebel Doeberitz M., Schirmacher P., Weitz J., Grabe N., Jager D. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 2009, 9:1.
33. Harrison J.C., Dean P.J., el-Zeky F., Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994, 25:498-505.
34. Lee W.S., Park S., Lee W.Y., Yun S.H., Chun H.K. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010, 116:5188-5199.
35. Lugli A., Karamitopoulou E., Panayiotides I., Karakitsos P., Rallis G., Peros G., Iezzi G., Spagnoli G., Bihl M., Terracciano L., et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer 2009, 101:1382-1392.
36. Menon A.G., Janssen-van Rhijn C.M., Morreau H., Putter H., Tollenaar R.A., van de Velde C.J., Fleuren G.J., Kuppen P.J. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004, 84:493-501.
37. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J.A., Giovannucci E., Dranoff G., Fuchs C.S., Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222:350-366.
38. Prall F., Duhrkop T., Weirich V., Ostwald C., Lenz P., Nizze H., Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004, 35:808-816.
39. Dahlin A.M., Henriksson M.L., Van Guelpen B., Stenling R., Oberg A., Rutegard J., Palmqvist R. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011, 24:671-682.
40. Nagtegaal I.D., Marijnen C.A., Kranenbarg E.K., Mulder-Stapel A., Hermans J., van de Velde C.J., van Krieken J.H. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 2001, 1:7.
41. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., Suzuki Y., Shintaku I., Nagura H., Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001, 61:5132-5136.
42. Karja V., Aaltomaa S., Lipponen P., Isotalo T., Talja M., Mokka R. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005, 25:4435-4438.
43. Richardsen E., Uglehus R.D., Due J., Busch C., Busund L.T. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology 2008, 53:30-38.
44. Vesalainen S., Lipponen P., Talja M., Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994, 30A:1797-1803.
45. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26:4410-4417.
46. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
47. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12:5423-5434.
48. Ito N., Suzuki Y., Taniguchi Y., Ishiguro K., Nakamura H., Ohgi S. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005, 25:2027-2031.
49. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., Aokage K., Saijo N., Nishiwaki Y., Gemma A., et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.
50. Broussard E.K., Disis M.L. TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol 2011, 29:601-603.
51. Galon J., Pages F., Marincola F.M., Thurin M., Trinchieri G., Fox B.A., Gajewski T.F., Ascierto P.A. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1.
52. Galon J., Franck P., Marincola F.M., Angell H.K., Thurin M., Lugli A., Zlobec I., Berger A., Bifulco C., Botti G., et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 10:205.
53. Bindea G., Mlecnik B., Fridman W.H., Pages F., Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010, 22:215-222.
54. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
55. Riley R.D., Heney D., Jones D.R., Sutton A.J., Lambert P.C., Abrams K.R., Young B., Wailoo A.J., Burchill S.A. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004, 10:4-12.
56. Galea M.H., Ellis I.O., Elston C.W., Blamey R.W. Node negative breast cancer prognosis and DNA ploidy. Br J Surg 1992, 79:181.
57. Galea M.H., Blamey R.W., Elston C.E., Ellis I.O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
58. Huncharek M., Muscat J., Geschwind J.F. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999, 20:1507-1510.
59. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
60. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
61. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., van't Veer L.J., Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
62. Ma X.J., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle J.T., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
63. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sorlie T., Dai H., He Y.D., van't Veer L.J., Bartelink H., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005, 102:3738-3743.
64. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
65. Fearnhead N.S., Britton M.P., Bodmer W.F. The ABC of APC. Hum Mol Genet 2001, 10:721-733.
66. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
67. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
68. Terme M., Pernot S., Marcheteau E., Sandoval F., Benhamouda N., Colussi O., Dubreuil O., Carpentier A.F., Tartour E., Taieb J. VEGFA-VEGF Receptor pathway blockade inhibits tumor-induced regulatory T cell proliferation in colorectal cancer. Cancer Res 2012, 73:539-549.
69. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
70. Stagg J., Loi S., Divisekera U., Ngiow S.F., Duret H., Yagita H., Teng M.W., Smyth M.J. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011, 108:7142-7147.
71. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., Alaparthy S., Berman D., Jure-Kunkel M., Siemers N.O., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:1019-1031.
72. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
73. Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., Guida M., Hyams D.M., Gomez H., Bastholt L., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204.
74. Sharma A., Shah S.R., Illum H., Dowell J. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs 2012, 72:2207-2222.
75. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.
76. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
77. Apetoh L., Tesniere A., Ghiringhelli F., Kroemer G., Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008, 68:4026-4030.
78. Morris M., Platell C., Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008, 14:1413-1417.
79. Ascierto M.L., De Giorgi V., Liu Q., Bedognetti D., Spivey T.L., Murtas D., Uccellini L., Ayotte B.D., Stroncek D.F., Chouchane L., et al. An immunologic portrait of cancer. J Transl Med 2011, 9:146.
80. Ogino S., Galon J., Fuchs C.S., Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011, 8:711-719.